Glaukos Corporation
Glaukos Corporation (GKOS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GKOS · as of Jun 8, 2026
Key Statistics
Explore Glaukos Corporation Data
gkos stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 24 · Buy rate: 75.0%
The GKOS analyst consensus is Buy, based on ratings from 24 Wall Street analysts over the past 3 months. The average 12-month price target is $149.00, representing +19.20% upside from the current price of $125.00.
Competitors & Peers
gkos competitorsGKOS
ACLX
ALKS
ARWR
BLCO
BRKRStock Performance
Full HistoryAbout Glaukos Corporation
Glaukos Corporation an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. …
what is glaukos corporation · gkos stock overview · glaukos corporation company profile · who is glaukos corporation ceo · gkos NYSE · glaukos corporation headquarters · glaukos corporation business segments
About Stock Overview & Key Data
Glaukos Corporation (GKOS) is a Healthcare company in the Medical - Devices industry, listed on NYSE since Jun 25, 2015. As of the latest trading session, GKOS stock price is $125.00, with a market capitalization of $7.3B. The stock has returned +32.08% over the past 12 months and +10.71% year-to-date.
According to 24 Wall Street analysts, the consensus rating for Glaukos Corporation stock is Buy, with an average 12-month price target of $149.00. In fiscal year 2025, Glaukos Corporation reported revenue of $507.4M and net income of -$187.7M. For detailed data — including Glaukos Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Glaukos Corporation (GKOS) stock price is $125.00. The stock is traded on NYSE under the ticker symbol GKOS. The 52-week range is $73.16 – $148.11.